- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03937921
Dotarem Evaluation for Myocardial Perfusion CMR
The overall goal of this study is to investigate the signal intensity and relaxation rate characteristics of gadoterate meglumine (Dotarem, Guerbet, USA) enhanced myocardium during rest and stress perfusion cardiovascular magnetic resonance (CMR) compared to gadobutrol (Gadavist) to prove that Dotarem provides constantly high myocardial relaxation necessary for accurate quantitative perfusion evaluation.
The purpose of this study is to compare two types of contrast that patients receive during cardiac MRI scans to visualize the blood flow in the cardiac muscle. Both contrasts are used in standard of care procedures, and the one administered for each patient will be randomly selected. The length of the MRI study all procedures are the same as the clinically indicated scan.
Study Overview
Status
Intervention / Treatment
Detailed Description
The overall goal of this study is to investigate the signal intensity and relaxation rate characteristics of gadoterate meglumine (Dotarem, Guerbet, USA) enhanced myocardium during rest and stress perfusion cardiovascular magnetic resonance (CMR) compared to gadobutrol (Gadavist) to prove that Dotarem provides constantly high myocardial relaxation necessary for accurate quantitative perfusion evaluation. Within this overall goal, the following specific aims will be pursued:
- Aim 1: To test the hypothesis that the signal intensity enhancement during Dotarem myocardial stress/rest perfusion is relatively constant, providing linear and stable enhancement in the myocardium, and is not inferior compared to gadobutrol (Gadavist).
- Aim 2: To test the hypothesis that the relaxation rate enhancement during Dotarem myocardial rest perfusion is uniform in the myocardium.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Mark Ghent, BA
- Phone Number: 843-876-7148
- Email: ghent@musc.edu
Study Contact Backup
- Name: Vincent Giovagnoli, BS
- Phone Number: 843-876-4922
- Email: giovagnv@musc.edu
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Recruiting
- Medical University of South Carolina
-
Contact:
- Danielle Dargis
- Phone Number: 843-876-4922
- Email: dargis@musc.edu
-
Contact:
- Tyler Leonard
- Phone Number: 843-876-4922
- Email: leornarty@musc.edu
-
Principal Investigator:
- U. Joseph Schoepf
-
Sub-Investigator:
- Akos Varga-Szemes
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Aim 1
Inclusion criteria:
To be eligible for the study: (All answers must be "YES" for subject to be eligible.)
- Subject must be referred for a clinically indicated contrast-enhanced stress myocardial perfusion MRI scan out of concern of suspected myocardial ischemia.
- Subject must be older than 18 years of age.
- Subject must provide written informed consent prior to any study-related procedures being performed.
- Subject must be willing to comply with all clinical study procedures.
Exclusion Criteria:
The presence of the following excludes subjects from the study: (All answers must be "NO" for subject to be eligible.)
Subject is a pregnant or nursing female. Exclude the possibility of pregnancy:
- By testing (serum or urine beta HCG) within 24 hours before study date, or
- By surgical sterilization, or
- Post-menopausal, with minimum one (1) year history without menses.
- Subject has an implanted cardiac pacemaker or implantable defibrillator.
- Subject has a ferromagnetic vascular clip.
- Subject has a neurostimulation system (e.g. TENS-Unit).
- Subject has any type of cochlear implant.
- Subject has ocular foreign body (e.g. metal shavings).
- Subject carries any implanted device (e.g. insulin pump, drug infusion device).
- Subject has shrapnel, bullet, or other type of metal fragments within the body.
- Subject has an acute psychiatric disorder or is cognitively impaired.
- Subject is using or is dependent on substances of abuse.
- Subject is unwilling to comply with the requirements of the protocol.
- Subject is in acute unstable condition.
- Subject has an allergy against gadolinium based contrast agents or pharmaceutical stressors used in this study.
- Subject has impaired renal function (creatinine > 1.5 mg/dl).
- Subject presenting with acute coronary syndrome.
- Positive cardiac enzymes positive troponin, CK-MB, or myosin
- ST-elevations, new transient ST changes greater than 0.05mV or T- wave inversions with symptoms
Aim 2
Inclusion criteria:
To be eligible for the study: (All answers must be "YES" for subject to be eligible.)
- Subject must be referred for a clinically indicated contrast-enhanced stress myocardial perfusion MRI scan out of concern of suspected myocardial ischemia.
- Subject must be older than 18 years of age.
- Subject must provide written informed consent prior to any study-related procedures being performed.
- Subject must be willing to comply with all clinical study procedures.
Exclusion Criteria:
The presence of the following excludes subjects from the study: (All answers must be "NO" for subject to be eligible.)
Subject is a pregnant or nursing female. Exclude the possibility of pregnancy:
- By testing (serum or urine beta HCG) within 24 hours before study date, or
- By surgical sterilization, or
- Post-menopausal, with minimum one (1) year history without menses.
- Subject has an implanted cardiac pacemaker or implantable defibrillator.
- Subject has a ferromagnetic vascular clip.
- Subject has a neurostimulation system (e.g. TENS-Unit).
- Subject has any type of cochlear implant.
- Subject has ocular foreign body (e.g. metal shavings).
- Subject carries any implanted device (e.g. insulin pump, drug infusion device).
- Subject has shrapnel, bullet, or other type of metal fragments within the body.
- Subject has an acute psychiatric disorder or is cognitively impaired.
- Subject is using or is dependent on substances of abuse.
- Subject is unwilling to comply with the requirements of the protocol.
- Subject is in acute unstable condition.
- Subject has an allergy against gadolinium based contrast agents used in this study.
- Subject has impaired renal function (creatinine > 1.5 mg/dl).
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group 1 - Dotarem
Group 1 (n=30) will receive the clinically approved gadoterate meglumine (Dotarem, 0.1mmol/kg) as the contrast agent for their clinical perfusion study
|
|
Group 2 - Gadavist
Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as the contrast agent.
|
Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as contrast agent.
The contrast agents will be administered at a flow rate of 5.0 ml/s for both groups.
In this study aim, all imaging protocols will comply with standard of care and only the perfusion data will be post-processed and analyzed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Signal intensity of gadoterate meglumine during perfusion cardiovascular magnetic resonance
Time Frame: 1 year
|
Characteristics of signal intensity changes and absolute myocardial blood flow using the MASS Research Software; signal intensity-time curves from the perfusion data
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relaxation rate characteristics of gadoterate meglumine during perfusion cardiovascular magnetic resonance
Time Frame: 1 year
|
The uniformity of T1 and R1 (inverse T1) evaluated using the MASS Research Software; equilibrium T1 maps generated by pre-contrast T1 and repeat inversion recovery images during the perfusion of the coronary arteries
|
1 year
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 80969
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Magnetic Resonance Imaging
-
BayerCompletedMagnetic Resonance Imaging | Magnetic Resonance AngiographyPoland, China, France, Germany, Hungary, Korea, Republic of, South Africa, Spain, Thailand, Taiwan, Czech Republic, Hong Kong, Italy, Kazakhstan, Russian Federation, Bosnia and Herzegovina, Greece, Canada, Vietnam, Kyrgyzstan
-
Centre Hospitalier Régional Metz-ThionvilleUniversity of LorraineNot yet recruitingMagnetic Resonance ImagingFrance
-
Jessa HospitalActive, not recruitingMagnetic Resonance ImagingBelgium
-
BayerCompletedMagnetic Resonance ImagingUnited States, Korea, Republic of, France, Germany, Italy, Switzerland, United Kingdom
-
Boston Scientific CorporationCompletedMagnetic Resonance ImagingSpain, Hong Kong, Germany, Israel, United Kingdom, Italy, United States, Malaysia, Belgium
-
Centre Hospitalier Universitaire, AmiensCompletedMagnetic Resonance ImagingFrance
-
MegaPro Biomedical Co. Ltd.CompletedMagnetic Resonance ImagingTaiwan
-
BayerCompletedMagnetic Resonance ImagingJapan
-
BayerCompletedMagnetic Resonance ImagingPhilippines
-
BayerCompletedMagnetic Resonance Imaging | Myocardial Perfusion ImagingSwitzerland, Germany, Austria, Poland
Clinical Trials on Gadavist 15Ml Solution for Injection
-
Northwestern UniversityRecruiting
-
Charite University, Berlin, GermanyUniversity of GöttingenUnknownHeart Failure | Iron-deficiencyGermany
-
Subtle MedicalBayerEnrolling by invitation
-
Boehringer IngelheimRecruitingNetherton SyndromeBelgium, United Kingdom, Australia, Germany, China, Malaysia, United States, Japan, France, Israel, Bulgaria, Italy, Switzerland, Austria, Netherlands, Portugal
-
10xBio, LLCActive, not recruitingSubmental FatUnited States
-
GlaxoSmithKlineCompleted
-
10xBio, LLCTherapeutics, Inc.Active, not recruitingSubcutaneous Fat DisorderUnited States
-
Ferring PharmaceuticalsCompleted
-
Regional Hospital HolstebroWithdrawnSyndrome of Inappropriate ADH-secretionDenmark
-
Mayo ClinicRecruitingLower Urinary Tract Obstructive Syndrome | Renal Failure Congenital | Congenital Renal Anomaly Nos | Renal Agenesis and DysgenesisUnited States